Back to Global NewsPublished: 28 Feb 2026Download AppJoin TelegramWhy Ascendis' Dwarfism Drug Could Flip the Biotech Playbook: Risks & Rewards#Ascendis Pharma#Yuviwel#Biotech#FDA Approval#Rare Diseases#InvestingDownload AppJoin CommunityShare Article